MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.27% | -38.25% | 12.41% | -28.86% | -45.84% |
| Total Depreciation and Amortization | 0.40% | 96.30% | -70.95% | 270.74% | 2.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 164.32% | -36.60% | 765.55% | -118.21% | 9.30% |
| Change in Net Operating Assets | 1,902.35% | -222.22% | 90.54% | -147.09% | 255.70% |
| Cash from Operations | 18.31% | -42.97% | 21.32% | -91.78% | 9.37% |
| Capital Expenditure | -- | 100.00% | 80.07% | -33.03% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.17% | 56.81% | 138.25% | -351.92% | 166.57% |
| Cash from Investing | 0.17% | 56.91% | 138.18% | -352.79% | 166.42% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -33.64% | 65.60% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | -- | -100.00% | 48,421.57% | -17.65% | -- |
| Foreign Exchange rate Adjustments | -120.49% | 1,680.68% | -120.76% | 230.40% | -1,811.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.46% | -61.47% | 146.68% | -694.05% | 128.42% |